117 related articles for article (PubMed ID: 36456139)
1. The Expression of Histone Acetyltransferase KAT6A in Non-small Cell Lung Cancer.
Partynska A; Piotrowska A; Pawelczyk K; Rzechonek A; Ratajczak-Wielgomas K; Podhorska-Okolow M; Dziegiel P
Anticancer Res; 2022 Dec; 42(12):5731-5741. PubMed ID: 36456139
[TBL] [Abstract][Full Text] [Related]
2. Matrix stiffness-induced upregulation of histone acetyltransferase KAT6A promotes hepatocellular carcinoma progression through regulating SOX2 expression.
Zhao W; Mo H; Liu R; Chen T; Yang N; Liu Z
Br J Cancer; 2022 Jul; 127(2):202-210. PubMed ID: 35332266
[TBL] [Abstract][Full Text] [Related]
3. KAT6A, a chromatin modifier from the 8p11-p12 amplicon is a candidate oncogene in luminal breast cancer.
Turner-Ivey B; Guest ST; Irish JC; Kappler CS; Garrett-Mayer E; Wilson RC; Ethier SP
Neoplasia; 2014 Aug; 16(8):644-55. PubMed ID: 25220592
[TBL] [Abstract][Full Text] [Related]
4. SATB1 Level Correlates with Ki-67 Expression and Is a Positive Prognostic Factor in Non-small Cell Lung Carcinoma.
Glatzel-Plucinska N; Piotrowska A; Grzegrzolka J; Olbromski M; Rzechonek A; Dziegiel P; Podhorska-Okolow M
Anticancer Res; 2018 Feb; 38(2):723-736. PubMed ID: 29374696
[TBL] [Abstract][Full Text] [Related]
5. Different pattern of expression of cellular oncogenes in human non-small-cell lung cancer cell lines.
Kiefer PE; Wegmann B; Bacher M; Erbil C; Heidtmann H; Havemann K
J Cancer Res Clin Oncol; 1990; 116(1):29-37. PubMed ID: 1690210
[TBL] [Abstract][Full Text] [Related]
6. GRK5 functions as an oncogenic factor in non-small-cell lung cancer.
Jiang LP; Fan SQ; Xiong QX; Zhou YC; Yang ZZ; Li GF; Huang YC; Wu MG; Shen QS; Liu K; Yang CP; Chen YB
Cell Death Dis; 2018 Feb; 9(3):295. PubMed ID: 29463786
[TBL] [Abstract][Full Text] [Related]
7. Histone Acetyltransferase KAT6A Upregulates PI3K/AKT Signaling through TRIM24 Binding.
Lv D; Jia F; Hou Y; Sang Y; Alvarez AA; Zhang W; Gao WQ; Hu B; Cheng SY; Ge J; Li Y; Feng H
Cancer Res; 2017 Nov; 77(22):6190-6201. PubMed ID: 29021135
[TBL] [Abstract][Full Text] [Related]
8. Inhibitors of histone acetyltransferases KAT6A/B induce senescence and arrest tumour growth.
Baell JB; Leaver DJ; Hermans SJ; Kelly GL; Brennan MS; Downer NL; Nguyen N; Wichmann J; McRae HM; Yang Y; Cleary B; Lagiakos HR; Mieruszynski S; Pacini G; Vanyai HK; Bergamasco MI; May RE; Davey BK; Morgan KJ; Sealey AJ; Wang B; Zamudio N; Wilcox S; Garnham AL; Sheikh BN; Aubrey BJ; Doggett K; Chung MC; de Silva M; Bentley J; Pilling P; Hattarki M; Dolezal O; Dennis ML; Falk H; Ren B; Charman SA; White KL; Rautela J; Newbold A; Hawkins ED; Johnstone RW; Huntington ND; Peat TS; Heath JK; Strasser A; Parker MW; Smyth GK; Street IP; Monahan BJ; Voss AK; Thomas T
Nature; 2018 Aug; 560(7717):253-257. PubMed ID: 30069049
[TBL] [Abstract][Full Text] [Related]
9. KAT6A and ENL Form an Epigenetic Transcriptional Control Module to Drive Critical Leukemogenic Gene-Expression Programs.
Yan F; Li J; Milosevic J; Petroni R; Liu S; Shi Z; Yuan S; Reynaga JM; Qi Y; Rico J; Yu S; Liu Y; Rokudai S; Palmisiano N; Meyer SE; Sung PJ; Wan L; Lan F; Garcia BA; Stanger BZ; Sykes DB; Blanco MA
Cancer Discov; 2022 Mar; 12(3):792-811. PubMed ID: 34853079
[TBL] [Abstract][Full Text] [Related]
10. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
11. BCL11A Expression in Non-Small Cell Lung Cancers.
Kątnik E; Gomułkiewicz A; Piotrowska A; Grzegrzółka J; Kmiecik A; Ratajczak-Wielgomas K; Urbaniak A; Glatzel-Plucińska N; Błasiak P; Dzięgiel P
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37372998
[TBL] [Abstract][Full Text] [Related]
12. Increased expression of 17-beta-hydroxysteroid dehydrogenase type 1 in non-small cell lung cancer.
Drzewiecka H; Gałęcki B; Jarmołowska-Jurczyszyn D; Kluk A; Dyszkiewicz W; Jagodziński PP
Lung Cancer; 2015 Feb; 87(2):107-16. PubMed ID: 25564397
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancer.
Sharma S; Chung CY; Uryu S; Petrovic J; Cao J; Rickard A; Nady N; Greasley S; Johnson E; Brodsky O; Khan S; Wang H; Wang Z; Zhang Y; Tsaparikos K; Chen L; Mazurek A; Lapek J; Kung PP; Sutton S; Richardson PF; Greenwald EC; Yamazaki S; Jones R; Maegley KA; Bingham P; Lam H; Stupple AE; Kamal A; Chueh A; Cuzzupe A; Morrow BJ; Ren B; Carrasco-Pozo C; Tan CW; Bhuva DD; Allan E; Surgenor E; Vaillant F; Pehlivanoglu H; Falk H; Whittle JR; Newman J; Cursons J; Doherty JP; White KL; MacPherson L; Devlin M; Dennis ML; Hattarki MK; De Silva M; Camerino MA; Butler MS; Dolezal O; Pilling P; Foitzik R; Stupple PA; Lagiakos HR; Walker SR; Hediyeh-Zadeh S; Nuttall S; Spall SK; Charman SA; Connor T; Peat TS; Avery VM; Bozikis YE; Yang Y; Zhang M; Monahan BJ; Voss AK; Thomas T; Street IP; Dawson SJ; Dawson MA; Lindeman GJ; Davis MJ; Visvader JE; Paul TA
Cell Chem Biol; 2023 Oct; 30(10):1191-1210.e20. PubMed ID: 37557181
[TBL] [Abstract][Full Text] [Related]
14. The key roles of the lysine acetyltransferases KAT6A and KAT6B in physiology and pathology.
Wiesel-Motiuk N; Assaraf YG
Drug Resist Updat; 2020 Dec; 53():100729. PubMed ID: 33130515
[TBL] [Abstract][Full Text] [Related]
15. Small nucleolar RNA 42 acts as an oncogene in lung tumorigenesis.
Mei YP; Liao JP; Shen J; Yu L; Liu BL; Liu L; Li RY; Ji L; Dorsey SG; Jiang ZR; Katz RL; Wang JY; Jiang F
Oncogene; 2012 May; 31(22):2794-804. PubMed ID: 21986946
[TBL] [Abstract][Full Text] [Related]
16. Pantothenate and L-Carnitine Supplementation Improves Pathological Alterations in Cellular Models of KAT6A Syndrome.
Munuera-Cabeza M; Álvarez-Córdoba M; Suárez-Rivero JM; Povea-Cabello S; Villalón-García I; Talaverón-Rey M; Suárez-Carrillo A; Reche-López D; Cilleros-Holgado P; Piñero-Pérez R; Sánchez-Alcázar JA
Genes (Basel); 2022 Dec; 13(12):. PubMed ID: 36553567
[TBL] [Abstract][Full Text] [Related]
17. Interferon regulatory factor 4 (IRF4) is overexpressed in human non‑small cell lung cancer (NSCLC) and activates the Notch signaling pathway.
Qian Y; Du Z; Xing Y; Zhou T; Chen T; Shi M
Mol Med Rep; 2017 Nov; 16(5):6034-6040. PubMed ID: 28849037
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of Pokemon in non-small cell lung cancer and foreshowing tumor biological behavior as well as clinical results.
Zhao ZH; Wang SF; Yu L; Wang J; Chang H; Yan WL; Zhang J; Fu K
Lung Cancer; 2008 Oct; 62(1):113-9. PubMed ID: 18550205
[TBL] [Abstract][Full Text] [Related]
19. Analysis of MAT3 gene expression in NSCLC.
Zheng S; Du Y; Chu H; Chen X; Li P; Wang Y; Ma Y; Wang H; Zang W; Zhang G; Zhao G
Diagn Pathol; 2013 Oct; 8():166. PubMed ID: 24107548
[TBL] [Abstract][Full Text] [Related]
20. Long Noncoding RNA SNHG6 Promotes Proliferation and Inhibits Apoptosis in Non-small Cell Lung Cancer Cells by Regulating miR-490-3p/RSF1 Axis.
Dong Z; Liu H; Zhao G
Cancer Biother Radiopharm; 2020 Jun; 35(5):351-361. PubMed ID: 32202941
[No Abstract] [Full Text] [Related]
[Next] [New Search]
